deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT05020665

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia

Sponsor: Kronos Bio

Updated 20 times since 2021 Last updated: Dec 19, 2023 Started: Nov 24, 2021 Primary completion: Mar 30, 2023 Completion: Mar 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Termination was due to significant challenges associated with study enrollment in a genetic subset of fit participants in the front-line acute myeloid leukemia (AML) setting and other challenges associated with post-COVID impacts.

Other terminated trials from Kronos Bio

More terminations from Kronos Bio

This PHASE3 trial investigates Nucleophosmin 1-mutated Acute Myeloid Leukemia and is currently terminated or withdrawn. Kronos Bio leads this study, which shows 20 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Feb 2024 · 7 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jul 2023 — Feb 2024 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

Show 15 earlier versions
  1. May 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  6. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  7. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  8. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  9. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  10. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  11. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  12. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  13. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  14. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  15. Sep 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kronos Bio
Data source: Kronos Bio

For direct contact, visit the study record on ClinicalTrials.gov .